COVID-19 Emergency Ventilator

In response to the COVID-19 outbreak, Imperial’s experts in medical device design (bioengineering) – and a clinician treating infected patients – have designed an emergency ventilator that can be built to meet MHRA and FDA requirements using generic parts.  JAMVENT provides a simple, low-cost solution to ventilator shortages worldwide, particularly for health services in developing countries. Plus the robust design also makes it suitable for long term use beyond current COVID-19 needs.

The design document for the JAMVENT ventilator can be requested by those wishing to develop ventilators for their local healthcare providers and includes a list of parts and a software spec.

We welcome enquiries from health organisations, manufacturers and donors interested in working with us to take JAMVENT from design to manufacture.

 

Design benefits

  • Long term use – not specific to the COVID-19 crisis
  • Easy to manufacture from low cost components (estimated at around £1,500 in the UK)
  • Does not require specific pressure transducers or solenoids
  • Parts can be sourced from various manufacturers – avoiding supply-chain bottlenecks
  • No specialist or medical supply chain components – and no balloons
  • Simple electronics
  • Doesn’t require gas to drive it – unlike some others – which is critical where gas supply is limited.
  • Employs fluid mechanical design principles

 

Ventilator design meets clinicians needs

  • PEEP controllable electronically
  • Pressure Regulated Volume Control (PRVC) mode
  • Supports spontaneous breath
  • Maintains PEEP during suctioning

Performance evidence

Evidence that the JAMVENT prototype can perform to MHRA and ISO 80601 tests can be downloaded here.

It also highlights PRVC and spontaneous mode performance and how it can maintain PEEP during suctioning – critical functions of ICU ventilators for COVID-19 patients.

 

JAMVENT ventilator in action – click to view a video

 

Ventilator system

 


Creators of the emergency ventilator design

  • Project and Technical Lead – Dr Joseph Sherwood – RAEng Research Fellow, Department of Bioengineering. Research areas include biofluid mechanics, flow measurement/control, device design for research.
  • Clinical Lead – Dr. Jakob Mathiszig-Lee – Honorary Research Fellow and Senior Anaesthetic Registrar at the Royal Brompton Hospital. Department of Surgery and Cancer.
  • Project Manager – Prof James Moore – The Bagrit Chair in Medical Device Design, Department of Bioengineering. Research areas include biofluid mechanics, cardiovascular device design, device translation.
  • Co-Technical Lead – Dr Michael Madekurozwa, Department of Bioengineering. Research areas include experimental biofluid dynamics, design and implementation of tools, hardware and software for use in research.

Related Insights

Transport – sector’s response to COVID-19

Transport – sector’s response to COVID-19

As a result of the COVID-19 outbreak, transport providers have to change how they manage their organisations and serve their customers. The Transport Strategy Centre at Imperial have summarised these practices and approaches to help others optimise their responses. read more

Do bots spread fake news?

Do bots spread fake news?

If bots aren’t responsible for spreading fake news, could automated systems form part of the solution, helping to identify false stories and check their spread? read more

Pandemics and privacy

Pandemics and privacy

Contact tracing apps will take and keep some data from users. This insight discusses ways of minimising privacy implications. read more

Related case studies

Cystic Fibrosis clinical advisory board

Cystic Fibrosis clinical advisory board

Our consultants shared their expertise in Cystic Fibrosis (CF), drug development and clinical trials to help Proteostasis Therapeutics assess the combination of compounds aimed at treatments to improve lung function. read more

Hepatitis C genotype and drug resistance testing

Hepatitis C genotype and drug resistance testing

Genotype and resistance testing for new direct-acting antiviral (DAA) drugs designed to treat Hepatitis C virus (HCV). read more

Global adoption and regulation of electronic medical records

Global adoption and regulation of electronic medical records

Our consultants shared their expertise in clinical medicine to help IMS Health to assess the adoption, governance and regulatory landscape of electronic medical records (EMR) at different levels of healthcare systems around the world. read more

Latest news

New freshwater control system may resolve flood challenges

New freshwater control system may resolve flood challenges

A new river control system that uses smart technology has been shown to reduce downstream flooding, in a consultancy project carried out by Dr Wouter Buytaert for PyTerra. read more

Imperial’s experts to help clean-tech startups

Imperial’s experts to help clean-tech startups

Mayor of London Sadiq Khan announced the launch of Better Futures - an incubator focused on clean-tech startups to be led by Sustainable Bridges and delivered by the GLA, Imperial College London, Imperial Consultants and OPDC (Old Oak and Park Royal Development Corporation). read more

FREE Congenital Anomalies webinar – ON DEMAND

FREE Congenital Anomalies webinar – ON DEMAND

Register to see the second in our series of four, educational webinars exploring Fetal Medicine. We will explore the common (and less common) structural, chromosomal and genetic congenital abnormalities. Delivered by Imperial’s Professor Christoph Lees, and supported by GE HealthCare. read more